Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Clinical Trials
12
6 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2008
Active, not recruiting
6
50.0%
Completed
2
16.7%
Terminated
4
33.3%
No approval data available
• Calliditas Therapeutics' Nefecon demonstrated significant efficacy in Phase 3 trial, showing 31% reduction in proteinuria compared to 5% in placebo for IgA nephropathy treatment. • The drug showed favorable safety profile consistent with budesonide, with key secondary endpoint demonstrating 7% treatment benefit in estimated glomerular filtration rate versus placebo. • Company plans FDA filing for accelerated approval in Q1 2021, followed by EMA submission in H2, targeting 130,000-150,000 potential patients in US market.
• Aravive's batiraxcept demonstrated no significant difference in median progression-free survival compared to paclitaxel in platinum-resistant recurrent ovarian cancer patients. • The Phase III trial termination led to a significant drop in batiraxcept's Likelihood of Approval (LoA) for ovarian cancer, decreasing by 10 points to 1%. • The study found no detriment to overall survival and identified no new safety signals, despite the failure to meet the primary endpoint. • The trial compared batiraxcept in combination with paclitaxel versus placebo in combination with paclitaxel.
